Skip to content

Study · Not a test of the peptide alone · 2020

10 results

Epigenetic Therapy Promotes the Ratio of Th1/Th17 Lineage to Reverse Immune Evasion and Treat Leukemia Relapse Post-allogeneic Stem Cell Transplantation in Non-APL AML Patients.

Xi Y, Jingying D, Chenglong L, Hong Z, Rong Z, Xiaodong W, Chunsen W, Xiaobing H

Frontiers in molecular biosciences24 Aug 2021Cited by 10 (Europe PMC)

PMID34504867 (opens in a new tab)PMCIDPMC8421566 (opens in a new tab)DOI10.3389/fmolb.2020.595395 (opens in a new tab)PepBankPUB-34504867
Download PDFPubMedAsk about this study
Jump to 10 results

Summary

To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia). Twenty-four patients were enrolled in this observational study during April 2015 to May 2018. The most common adverse event was reversible CTCAE grade 2 thrombocytopenia (20/24). Strikingly, all 24 patients had response to this epigenetic regimen accompanied with decreased measurable residual disease. The overall survival rate is 79.2% (19/24), with a relapse-free survival rate of 79.2% (19/24). During this regimen treatment, Th1 cells and CD3+CD4-CD8+T cells increased, and Th17 cells decreased gradually. The status of high Th1 and low Th17 cells was still observed on the 3rd month after discontinuation of this regimen. Interestingly, the significantly elevated ratio of Th1/Th17 seemed to reflect the treatment-related immune effect, which may be a valuable marker to be monitored in the early-relapse stage for evaluating the efficacy and prognosis.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneObservational studySafety outcome

    In 24 patients with non-APL AML after transplant, a regimen of chidamide, decitabine and thymalfasin caused reversible grade 2 thrombocytopenia in 20 of 24 patients, the most common adverse event.

    In plain wordsIn patients with leukemia after transplant, the three-drug regimen most often caused a reversible drop in platelets.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableThrombocytopenia (CTCAE grade 2)
    Study

    n = 24

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    The most common adverse event was reversible CTCAE grade 2 thrombocytopenia (20/24).
    2 context sentences
    Summary · context
    To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia).
    Summary · context
    Twenty-four patients were enrolled in this observational study during April 2015 to May 2018.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    All 24 patients with non-APL AML relapse after transplant responded to a regimen of chidamide, decitabine and thymalfasin.

    In plain wordsIn patients with leukemia after transplant, all 24 responded to the three-drug regimen.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableResponse to the regimen
    Study

    n = 24

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    all 24 patients had response to this epigenetic regimen
    2 context sentences
    Summary · context
    To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia).
    Summary · context
    Twenty-four patients were enrolled in this observational study during April 2015 to May 2018.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    In patients with non-APL AML after transplant, the regimen of chidamide, decitabine and thymalfasin was accompanied by decreased measurable residual disease.

    In plain wordsIn patients with leukemia after transplant, leftover cancer cells decreased during the three-drug regimen.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseMeasurable residual disease
    Study

    n = 24

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    accompanied with decreased measurable residual disease.
    2 context sentences
    Summary · context
    To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia).
    Summary · context
    Twenty-four patients were enrolled in this observational study during April 2015 to May 2018.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    In patients with non-APL AML after transplant, the overall survival rate with the regimen was 79.2% (19 of 24).

    In plain wordsIn patients with leukemia after transplant, 19 of 24 were alive after the three-drug regimen.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableOverall survival rate
    Study

    n = 24

    Outcome group
    Mortality · Cancer

    Measurements

    Overall survival rate
    79.2%
    regimen of chidamide, decitabine and thymalfasin

    Source sentences

    Summary
    The overall survival rate is 79.2% (19/24)
    2 context sentences
    Summary · context
    To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia).
    Summary · context
    Twenty-four patients were enrolled in this observational study during April 2015 to May 2018.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    In patients with non-APL AML after transplant, the relapse-free survival rate with the regimen was 79.2% (19 of 24).

    In plain wordsIn patients with leukemia after transplant, 19 of 24 stayed free of relapse after the three-drug regimen.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableRelapse-free survival rate
    Study

    n = 24

    Outcome group
    Mortality · Cancer

    Measurements

    Relapse-free survival rate
    79.2%
    regimen of chidamide, decitabine and thymalfasin

    Source sentences

    Summary
    with a relapse-free survival rate of 79.2% (19/24).
    2 context sentences
    Summary · context
    To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia).
    Summary · context
    Twenty-four patients were enrolled in this observational study during April 2015 to May 2018.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneObservational studyMechanism

    In patients with non-APL AML after transplant, Th1 cells increased during the regimen.

    In plain wordsIn patients with leukemia after transplant, Th1 immune cells rose during the three-drug regimen.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTh1 cells
    Study

    n = 24

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Th1 cells and CD3+CD4-CD8+T cells increased
    2 context sentences
    Summary · context
    To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia).
    Summary · context
    Twenty-four patients were enrolled in this observational study during April 2015 to May 2018.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07HumanNot a test of Thymosin alpha-1 aloneObservational studyMechanism

    In patients with non-APL AML after transplant, CD3+CD4-CD8+ T cells increased during the regimen.

    In plain wordsIn patients with leukemia after transplant, CD8-type T cells rose during the three-drug regimen.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD3+CD4-CD8+ T cells
    Study

    n = 24

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Th1 cells and CD3+CD4-CD8+T cells increased
    2 context sentences
    Summary · context
    To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia).
    Summary · context
    Twenty-four patients were enrolled in this observational study during April 2015 to May 2018.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  8. 08HumanNot a test of Thymosin alpha-1 aloneObservational studyMechanism

    In patients with non-APL AML after transplant, Th17 cells decreased gradually during the regimen.

    In plain wordsIn patients with leukemia after transplant, Th17 immune cells fell during the three-drug regimen.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTh17 cells
    Study

    n = 24

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Th17 cells decreased gradually.
    2 context sentences
    Summary · context
    To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia).
    Summary · context
    Twenty-four patients were enrolled in this observational study during April 2015 to May 2018.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  9. 09HumanNot a test of Thymosin alpha-1 aloneObservational studyMechanism

    In patients with non-APL AML after transplant, high Th1 and low Th17 cell levels persisted 3 months after the regimen was stopped.

    In plain wordsIn patients with leukemia after transplant, the immune cell pattern stayed three months after the regimen stopped.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableTh1 and Th17 status 3 months after discontinuation
    Study

    n = 24

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The status of high Th1 and low Th17 cells was still observed on the 3rd month after discontinuation of this regimen.
    2 context sentences
    Summary · context
    To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia).
    Summary · context
    Twenty-four patients were enrolled in this observational study during April 2015 to May 2018.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  10. 10HumanNot a test of Thymosin alpha-1 aloneObservational studyMechanism

    In patients with non-APL AML after transplant, the Th1/Th17 ratio rose significantly, which may reflect a treatment-related immune effect.

    In plain wordsIn patients with leukemia after transplant, the Th1/Th17 ratio rose during the three-drug regimen.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTh1/Th17 ratio
    Study

    n = 24

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    the significantly elevated ratio of Th1/Th17 seemed to reflect the treatment-related immune effect
    2 context sentences
    Summary · context
    To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia).
    Summary · context
    Twenty-four patients were enrolled in this observational study during April 2015 to May 2018.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.